Abstract:Background Reprogramming of amino acid metabolism is critical for tumor growth. We have reported that upregulation of pyrroline-5-carboxylate reductase 1 (PYCR1), a key enzyme in mitochondrial proline anabolism, contributes to gastric cancer (GC) progression and indicates poor survival. However, the PYCR1 expression profile in GC subtypes and the underlying mechanisms behind its upregulation, as well as the promotion of GC progression are not well-studied. Methods PYCR1 expression profiles in GC subtypes and stages of gastric carcinogenesis were assessed in different cohorts. Genetic alterations and epigenetic modulation in PYCR1 regulation were investigated in tumor tissues and GC cell lines. The effect of PYCR1 on GC progression was further investigated from the perspectives of mitochondrial function and intracellular metabolism. Results PYCR1 expression was significantly higher in intestinal-type GC and associated molecular subtypes in two independent GC cohorts. During the Correa cascade of gastric carcinogenesis, PYCR1 was continuously increased from normal gastric tissues to atrophic gastritis with or without intestinal metaplasia, through to dysplasia, and finally to cancerous lesions. Hypomethylation and p300-mediated H3K27ac acetylation activation in PYCR1 promotor synergistically facilitated PYCR1 transcription. PYCR1 depletion or overexpression attenuated or promoted GC cell proliferation, but did not have any effect on the cell cycle. PYCR1 inhibition decreased mitochondrial DNA copy number in GC cells, but had no effect on mitochondrial membrane potential, mitochondrial mass and oxidative stress response. Detection of intracellular metabolite profiles revealed that PYCR1 depletion had a significant effect on intracellular purine metabolism (hypoxanthine, inosine and adenosine monophosphate), which was associated with cell growth inhibition. Furthermore, depletion of PYCR1 restored mitochondrial networking via enhancing mitochondrial fusion, leading to inhibition of cell proliferation. Consistently, pharmacological enhancement with Mdivi-1 of mitochondrial fusion also brought about the similar effects. Conversely, PYCR1 overexpression promoted mitochondrial fission, contributing to tumor growth. Conclusions PYCR1 overexpression was heterogeneous in different GC subtypes, and an increase in PYCR1 was an early event in the multistep of gastric carcinogenesis. Epigenetic modulation synergistically contributes to PYCR1 upregulation in GC, resulting in tumor progression via enhancing mitochondrial fission and coupling with purine metabolic reprogramming. Collectively, PYCR1 might be a promising therapeutic target for GC.

PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification

Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma

Linc00901 Regulates Glucose Metabolism In Pancreatic Cancer.

Abstract 2389: LINC00901 Regulates Glucose Metabolism in Pancreatic Cancer

Pyrroline-5-carboxylate Reductase 1 Promotes Proliferation and Inhibits Apoptosis in Non-Small Cell Lung Cancer

Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers

PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma

Pyrroline-5-carboxylate Reductase 1 (PYCR1) Upregulation Contributes to Gastric Cancer Progression and Indicates Poor Survival Outcome

Deciphering the Effects of the PYCR Family on Cell Function, Prognostic Value, Immune Infiltration in ccRCC and Pan-Cancer

IDDF2022-ABS-0083 Epigenetic Induction of Mitochondrial Proline Synthase PYCR1 Promotes Gastric Cancer Progression by Regulating Mitochondrial Dynamics and Purine Metabolism

PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

IGF1R-phosphorylated PYCR1 facilitates ELK4 transcriptional activity and sustains tumor growth under hypoxia

Mitochondrial Pyruvate Carrier 1: a Novel Prognostic Biomarker That Predicts Favourable Patient Survival in Cancer

Effects of PYCR1 on Prognosis and Immunotherapy Plus Tyrosine Kinase Inhibition Responsiveness in Metastatic Renal Cell Carcinoma Patients

PCYT1A Suppresses Proliferation and Migration Via Inhibiting Mtorc1 Pathway in Lung Adenocarcinoma.

PYCR1 regulates TRAIL‐resistance in non‐small cell lung cancer cells by regulating the redistribution of death receptors

Lipolysis-Stimulated Lipoprotein Receptor Impairs Hepatocellular Carcinoma and Inhibits the Oncogenic Activity of YAP1 via PPPY Motif

PYCR, a key enzyme in proline metabolism, functions in tumorigenesis

Survival and clinicopathological significance of PYCR1 expression in cancer: a meta-analysis

GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway

LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway